REFERENCES
- Rouveix B. Clinical implications of multiple drug resistance efflux pumps of pathogenic bacteria. J Antimicrob Chemother 2007; 59: 1208–1209.
- Yoshida Bogaki M, Nakamura S, Ubukata K, Konno M. Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones. J Bacteriol 1990; 172: 6942–6949.
- Kaatz GW, McAleese F, Seo SM. Multidrug resistance in Staphylo-coccus aureus due to overexpression of a novel multidrug and toxin extru-sion (MATE) transport protein. Antimicrob Agents Chemother 2005; 49: 1857–1864.
- Baranova NN, Neyfakh AA. Apparent involvement of a multidrug transporter in the fluoroquinolone resistance of Streptococcus pneumoniae. Antimicrob Agents Chemother 1997; 41: 1396–1398.
- Garvey MI, Piddock Li. The efflux pump inhibitor reserpine selects multidrug-resistant Streptococcus pneumoniae strains that overexpress the ABC transporters PatA and PatB. Antimicrob Agents Chemother 2008; 52: 1677–1685.
- Okusu H, Ma D, Nikaido H. AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple-antibiotic-resistance (Mar) mutants. J Bacteriol 1996; 178: 306–308.
- Sanchez L, Pan W, Vinas M, Nikaido H. The acrAB homolog of Haemophilus influenzae codes for a functional multidrug efflux pump. J Bacteriol 1997; 179: 6855–6857.
- FraliCk JA. Evidence that ToIC is required for functioning of the Mar/AcrAB efflux pump of Escherichia coli. J Bacteriol 1996; 178: 5803–5805.
- Li XZ, Livermore DM, Nikaido H. Role of efflux pump(s) in intrinsic re-sistance of Pseudomonas aeruginosa: resistance to tetracycline, chloram-phenicol, and norfloxacin. Antimicrob Agents Chemother 1994; 38: 1732–1741.
- Ahmed M, Borsch CM, Neyfakh AA, Schuldiner S. Mutants of the Bacillus subtilis multidrug transporter Bmr with altered sensitivity to the an-tihypertensive alkaloid reserpine. J Biol Chem 1993; 268: 11086–11089.
- Kinoshita N, Unemoto T, Kobayashi H. Proton motive force is not obligatory for growth of Escherichia coli. J Bacteriol 1984; 160: 1074–1077.
- Cho H, Oh Y, Park S, Li Y. Concentration of CCCP should be opti-mized to detect the efflux system in quinolone-susceptible Escherichia coli. J Microbiol 2001; 39: 62–66.
- Li XZ, NikaidoEfflux-mediated drug resistance in bacteria: an up-date. Drugs 2009; 69: 1555–1623.
- Clinical and Laboratory Standards Institute. Methods for Dilution An-timicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard, Eighth Edition. CLSI document M7-A8. Clinical and Laboratory Standards Institute, Wayne, PA 2009.
- Louie A, Brown DL, Liu W, Kulawy RW, Deziel MR, Drusano GL. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae. Antimicrob Agents Chemother 2007; 51: 3988–4000.
- Kaatz GW, Moudgal VV, Seo SM. Identification and characterization of a novel efflux-related multidrug resistance phenotype in Staphylococcus aureus. J Antimicrob Chemother 2002; 50: 833–838.
- Gill MJ, Brenwald NP, Wise R. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneu-moniae. Antimicrob Agents Chemother 1999; 43: 187–189.
- Poole K. Efflux-mediated multiresistance in Gram-negative bacteria. Clin Microbiol Infect 2004; 10: 12–26.
- Morita Y, Kimura N, Mima T, Mizushima T, Tsuchiya T. Roles of MexXY- and MexAB-multidrug efflux pumps in intrinsic multidrug resistance of Pseudomonas aeruginosa PA01. J Gen Appl Microbiol 2001; 47: 27–32.